Shortened Pegloticase Infusions Feasible for Uncontrolled Gout, Reduces Treatment Burden
Infusion reaction rates and serum level lowering were similar between 120-minute and 60-minute infusion cohorts in the phase 4 AGILE study.
Megan Clowse, MD, MPH: Improving Disease and Reducing Corticosteroids in SLE With DZP
Clowse discussed findings from the phase 3 PHOENYCS GO trial presented at the 2024 ACR Convergence.
AI Assessments, Robotics Perform to Rheumatologist Levels in Joint Assessment
Data from 2 studies presented at ACR 2024 demonstrate the potential of AI to improve access to quality rheumatological assessments.
Ghaith Noaiseh, MD: Nipocalimab Improves Disease Measures, Reduces Autoantibodies in Sjogren’s
Noaiseh discussed data from the DAHLIAS study linking, for the first time, clinical responses, with autoantibody levels.
LEVI-04 Improved Outcomes in Knee Osteoarthritis Compared With Placebo
Over half of patients treated with LEVI-04 had at least a 50% reduction in pain and over 25% had at least a 75% reduction.
DZP Improves Disease Activity and Reduces Corticosteroid Use in SLE
The phase 3 PHOENYCS GO trial met its primary endpoint in achieving BICLA response at week 48 compared with placebo.
Vagus Nerve Stimulation Yields Responses in Refractory Rheumatoid Arthritis
Over one-third of participants had had inadequate responses or intolerance to at least 3 prior b/tsDMARDs.
Tofacitinib Not Superior to Placebo in Systemic Juvenile Arthritis Double-Blind Trial
However, fewer patients experienced flares in the tofacitinib group than in the placebo group, among other positive findings.
Laure Gossec, MD, PhD: Informing Physician Treatment Choices for Psoriatic Arthritis
Gossec discussed findings from the PsABIOnd study presented at the 2024 ACR Convergence.
Søren Andreas Just, MD, PhD: Developing AI to Mitigate Rheumatologist Shortages for Disease Assessment
Just discussed data from 2 studies demonstrating efficacy of AI assessment compared to clinician assessment.
Emapalumab May Improve Response Rates in MAS Treatment
Findings from the first and only controlled study for macrophage activation syndrome were presented at the ACR Convergence.
Shreena K. Gandhi, MBBS: Recognizing Fibromyalgia as a Continuous Variable, Trait Diagnosis
Gandhi discussed examining social security disability rates and how SSD criteria may clash with a trait disease like fibromyalgia.
Reducing Treatment Burden of Pegloticase for Uncontrolled Gout, with Orrin Troum, MD
Troum discussed positive efficacy and safety findings from the phase 4 AGILE study.
Exploring CAR T-cell Therapy for Rheumatic/Autoimmune Diseases With Georg Schett, MD
Schett discussed findings from 2 early studies of CD19 CAR T-cell therapy.
TCE Therapy Demonstrates Quick Responses for Systemic Lupus Erthematosus in Early Data
A-319 has been well-tolerated so far and dose-escalation is ongoing in the phase 1 trial.
John Stone, MD, MPH: Inebilizumab Efficacious for IgG4-Related Disease in MITIGATE Study
Stone discussed findings from the first randomized, double-blind, placebo-controlled trial for IgG4-related disease.
Glucocorticosteroid Use for Rheumatoid Arthritis Increases CVD, Infection Mortality Risk Even After Cessation
People who used GC for over 2 years and 3 years had elevated risks of CVD and infection-related mortality, respectively, that never returned to pre-GC use levels.
IL-18 Levels Associated With Long COVID Risk in People With Rheumatic Diseases
IL-18 levels were consistently lower across participants with different SARDs, remission status, and COVID-19 disease characteristics.
Study Finds Benefits and Risks in Cannabis Use for Rheumatoid Arthritis
While an effective and promising strategy for chronic pain relief, more research on long-term cannabis usage is needed.
Jinny Tavee, MD, Explores Neurosarcoidosis: The Great Mimicker
Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.
Tracy Frech, MD, MSCI: Digital Ischemia for the Rheumatologist
Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.
Smartphone-Based App Demonstrates Clinical Benefits in Fibromyalgia Management
At 12 weeks, significantly more patients with fibromyalgia receiving the smartphone-based intervention reported clinical improvements compared with the control group.
Fibromyalgia Symptoms Unimpacted by COVID-19 Pandemic
Findings may be related to a variety of influences including a slower life pace during the pandemic and resilience to prolonged stressors.
Patient Survey Leads to Better Understanding of Digital Health Preferences in Fibromyalgia
Common themes included preferring a standard list of symptoms, active training programs, and the desire for community.
Wristband, Coaching Program Improves QoL in Patients with Fibromyalgia
A clinically significant percentage of patients with fibromyalgia in the immediate intervention group had greater improvements in quality of life compared with patients in the delayed cohort.
Atul Deodhar, MD: Long-Term Data on Bimekizumab for Ankylosing Spondylitis
During this interview segment, Dr. Deodhar described his presentation at the ACR 2023 convergence on longitudinal data regarding bimekizumab for patients with this condition.
Patients with RA, Long COVID Significantly More Likely to Have Concomitant Fibromyalgia
Fibromyalgia was 3 times more common among patients with rheumatoid arthritis and Long COVID.
John Botson, MD: Pegloticase Plus Immunomodulator Enhances Gout Treatment
John Botson, MD, discusses his study examining real-world pegloticase plus immunomodulation co-therapy using data from an insurance claims database.
Philip J. Mease, MD: New Data on Guselkumab for Psoriatic Arthritis Patients
This interview segment with Dr. Mease featured a discussion about data presented at ACR 2023 on guselkumab and patients with psoriatic arthritis.
AR882 Lowers Serum Urate in Patients with Gout
At month 6, more patients in the AR882 75 mg cohort demonstrated complete resolution of ≥1 tophus compared with patients in the allopurinol cohort.
